EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Sequencing Immunotherapy in Relapsed or Refractory r/r DLBCL: Where Does Glofitamab Stand in the Post–CAR-T Era?

Birupaksha Biswas

International Journal of Contemporary Pathology · 21.08.2026 · 12 (2) · 1-3

DOI: 10.37506/yxdmbx52 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Contemporary Pathology, online erschienen am 21.08.2026. Verfasst von Birupaksha Biswas. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) continues to portend dismal outcomes following successive lines of therapy, particularly in patients progressing after chimeric antigen receptor T-cell interventions, thereby necessitating the urgent integration of novel immunotherapeutic paradigms. Glofitamab, a bispecific antibody with a distinctive 2:1 configuration targeting CD20 on malignant B cells and CD3 on T cells, has demonstrated clinically meaningful efficacy in heavily pretreated populations by potentiating endogenous cytotoxic immune responses. Across pivotal and real-world studies, glofitamab has yielded substantial response rates, including durable complete remissions, even among patients previously exposed to cellular therapies, while maintaining a manageable safety profile characterized predominantly by low-grade cytokine release syndrome mitigated through step-up dosing and anti-CD20 pretreatment. Notwithstanding these advances, questions pertaining to long-term durability, optimal therapeutic sequencing, and biomarker-driven patient selection remain unresolved. Collectively, these data position glofitamab as a compelling, off-the-shelf immunotherapeutic modality with the potential to recalibrate treatment strategies in aggressive B-cell lymphomas, pending further validation in earlier lines and combinatorial settings.

Zitieren

APA

Biswas, B. (2026). Sequencing Immunotherapy in Relapsed or Refractory r/r DLBCL: Where Does Glofitamab Stand in the Post–CAR-T Era?. International Journal of Contemporary Pathology, 12(2), 1-3. https://doi.org/10.37506/yxdmbx52

Vancouver

Biswas B. Sequencing Immunotherapy in Relapsed or Refractory r/r DLBCL: Where Does Glofitamab Stand in the Post–CAR-T Era?. International Journal of Contemporary Pathology. 2026;12(2):1-3. doi:10.37506/yxdmbx52

BibTeX
@article{Biswas2026,
  author = {Biswas, Birupaksha},
  title = {Sequencing Immunotherapy in Relapsed or Refractory r/r DLBCL: Where Does Glofitamab Stand in the Post–CAR-T Era?},
  journal = {International Journal of Contemporary Pathology},
  year = {2026},
  volume = {12},
  number = {2},
  pages = {1--3},
  doi = {10.37506/yxdmbx52}
}
Kostenlos starten →